Royalty Pharma (RPRX) Resumen de Acciones
Royalty Pharma plc opera como comprador de derechos biofarmacéuticos y financiador de la innovación en la industria biofarmacéutica en Estados Unidos. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 5/6 |
| Rendimiento pasado | 2/6 |
| Salud financiera | 3/6 |
| Dividendos | 2/6 |
RPRX Community Fair Values
Create NarrativeSee what 50 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Royalty Pharma plc
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$54.50 |
| Máximo en las últimas 52 semanas | US$54.64 |
| Mínimo de 52 semanas | US$32.21 |
| Beta | 0.40 |
| Cambio en 1 mes | 10.37% |
| Variación en 3 meses | 20.04% |
| Cambio de 1 año | 67.95% |
| Variación en 3 años | 68.31% |
| Variación en 5 años | 35.84% |
| Variación desde la OPV | 22.47% |
Noticias y actualizaciones recientes
Recent updates
Seeking Alpha • May 16
Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead
Summary Portfolio Receipts increased 10% to $925 million, while Royalty Receipts grew 13% to $887 million. Q1 confirmed a supportive, broad-based momentum. Management's 2030 Portfolio Receipts target of $4.7 billion increasingly appears conservative. Recent funding agreements with Johnson & Johnson, alongside prior collaborations with Biogen, Merck, and Teva, strengthen Royalty Pharma’s positioning. Capital flexibility and buybacks remain meaningful tailwinds. We remain buyers. Read the full article on Seeking Alpha
Actualización de narrativa • May 02
RPRX: Royalty Deals And Buybacks Will Shape Balanced Forward Outlook
Analysts have raised their blended price target on Royalty Pharma by several dollars to around the mid $40s, citing refined models that factor in slightly higher projected revenue growth, modestly lower profit margins, and continued benefits from recent royalty and financing deals such as the $250m Zymeworks agreement. Analyst Commentary Recent research on Royalty Pharma centers on how the updated price targets line up with the company’s deal pipeline, especially the $250m Zymeworks transaction.
Actualización de narrativa • Apr 17
RPRX: Diversified Royalty Portfolio And Recent Deals Will Support Future Upside
Analysts have nudged their price targets for Royalty Pharma modestly higher, with the average fair value estimate moving from about $59.28 to $60.61. They point to the company's diversified royalty portfolio, favorable deal terms such as the $250m Zymeworks financing, and the broader growth of the biopharma royalty market.Actualización de narrativa • Apr 03
RPRX: Royalty Deals And Dividend Policy Will Shape Balanced Forward Outlook
Analysts have raised the fair value estimate for Royalty Pharma to $46.00 from $40.86, citing updated models that reflect perceived strengths in its biopharma royalty exposure, portfolio diversification, and recent deal activity. Analyst Commentary Recent Street research around Royalty Pharma highlights both constructive and cautious views, giving you a mixed picture of how professionals are thinking about the stock.
Actualización de narrativa • Mar 19
RPRX: Royalty Deals And Buybacks Will Support Future Upside
Analysts have lifted their price target on Royalty Pharma to $51.56 from $51.00, citing updated Street views on its biopharma royalty exposure and recent deal activity as key supports for the revised fair value estimate. Analyst Commentary Recent Street commentary on Royalty Pharma highlights a mix of optimism around its royalty portfolio and business model, alongside some areas where investors may want to stay cautious on execution and deal risk.Actualización de narrativa • Mar 05
RPRX: Royalty Platform And Portfolio Diversification Will Drive Future Upside Potential
Analysts have nudged their targets higher on Royalty Pharma, with the consensus fair value estimate moving from $56.00 to about $59.28. They cite expectations for the company to benefit from growth in the biopharma royalty market, differentiation from competitors, and a more diversified portfolio.Actualización de narrativa • Feb 19
RPRX: Higher P/E Expectations And Buybacks Will Support Future Upside
Analysts have lifted their average price target on Royalty Pharma from about $46 to roughly $51, citing updated assumptions for fair value, discount rate, growth, margins, and a higher future P/E multiple as key drivers behind the move. Analyst Commentary Recent research coverage on Royalty Pharma has centered on refreshed models for fair value and updated assumptions around discount rates, growth, margins, and future P/E multiples.Artículo de análisis • Feb 11
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.235
Royalty Pharma plc's ( NASDAQ:RPRX ) dividend will be increasing from last year's payment of the same period to $0.235...Actualización de narrativa • Feb 05
RPRX: Pending XenoTherapeutics Deal And Dividend Increase Will Shape Near-Term Returns
Analysts have raised their price targets on Royalty Pharma by about $2 to an updated fair value of US$40.86, citing slightly higher long term revenue growth assumptions, a modestly higher future P/E multiple, and largely unchanged discount rate and profit margin inputs. Analyst Commentary Recent research on Royalty Pharma has been mixed, with some firms updating ratings and price targets around the company’s agreed acquisition by XenoTherapeutics at an estimated US$1.82 per share.Artículo de análisis • Jan 22
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's
Royalty Pharma plc's ( NASDAQ:RPRX ) dividend will be increasing from last year's payment of the same period to $0.235...Actualización de narrativa • Jan 21
RPRX: Pending XenoTherapeutics Deal And Hold Downgrade Will Limit Near-Term Upside
Analysts have trimmed their price expectations for Royalty Pharma, citing a revised fair value of $38.00 per share. This reflects updated views on revenue growth, profit margins, and future P/E multiples following the announced acquisition by XenoTherapeutics and the recent downgrade to Hold.Actualización de narrativa • Jan 07
RPRX: Agreed XenoTherapeutics Deal Will Highlight Upside In Royalty Portfolio Earnings Power
Analysts have nudged their fair value target for Royalty Pharma up to US$56.00 from US$55.00. This reflects updated assumptions on slower revenue growth, higher margins and a lower future P/E, while also factoring in the recent downgrade to Hold following the agreed acquisition by XenoTherapeutics at an estimated US$1.82 per share.Actualización de narrativa • Dec 15
RPRX Pending XenoTherapeutics Deal Will Anchor Shares Near Buyout Price
Analysts have nudged their price target on Royalty Pharma up by $1, to $38. This reflects modestly stronger revenue growth assumptions, offset by a slightly higher discount rate and lower projected profit margins, and incorporates the limited upside they see given the pending acquisition by XenoTherapeutics.Actualización de narrativa • Dec 01
RPRX: Share Buybacks Will Drive Value Upon Acquisition Completion
Analysts have revised Royalty Pharma's price target slightly upward from $45.54 to $45.98. They note that the pending acquisition by XenoTherapeutics has reduced uncertainty around the company’s valuation.Actualización de narrativa • Nov 17
RPRX: Share Buybacks And Acquisition Will Drive Outperformance After Downgrade
Analysts have raised Royalty Pharma's price target from $44.10 to $45.54, reflecting updated expectations for revenue growth. However, profit margins are anticipated to decrease following recent acquisition developments.Actualización de narrativa • Nov 02
RPRX: Upcoming Licensing Deals And Share Buybacks Will Drive Long-Term Upside
Narrative Update on Royalty Pharma: Analyst Price Target Revision Analysts have lowered their fair value estimate for Royalty Pharma from $44.86 to $44.10 per share. This revision is based on updated modeling of revenue growth and profit margins.Actualización de narrativa • Sep 04
Emerging Therapies And Licensing Will Expand Royalty Opportunities
Analysts maintain a positive outlook for Royalty Pharma, citing resilience amid sector underperformance, limited exposure to policy and macroeconomic risks, and anticipated seasonal strength, with the consensus price target unchanged at $43.27. Analyst Commentary Bullish analysts expect Q2 to be seasonally strong for large biopharma companies, supporting near-term performance.Artículo de análisis • Jul 06
Benign Growth For Royalty Pharma plc (NASDAQ:RPRX) Underpins Its Share Price
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...Artículo de análisis • May 31
Here's Why We Think Royalty Pharma (NASDAQ:RPRX) Is Well Worth Watching
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Seeking Alpha • Feb 13
Royalty Pharma: Delivering Growth With A Positive Story Ahead
Summary Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million, which demonstrate solid performance. MorphoSys bond redeployment further enhances higher-returning royalty opportunities. The company has a solid balance sheet with $1.4 billion in cash equivalents, which is worth considering. RPRX's valuation remains compelling, with a double-digit total yield (via buyback and dividend). Read the full article on Seeking AlphaSeeking Alpha • Jan 15
Royalty Pharma: Key Strategic Updates To Be Priced In
Summary Key strategic updates include acquiring RP Management LLC, simplifying the corporate structure, reducing costs, and enhancing shareholder alignment. A new $3 billion share repurchase program and a 5% dividend increase highlight strong capital allocation, maintaining financial flexibility and an investment-grade credit rating. The valuation remains compelling, with a 30% upside. Anticipated savings and buybacks suggest further EPS growth, reinforcing our overweight rating. Read the full article on Seeking AlphaSeeking Alpha • Nov 09
Royalty Pharma: Massive Opportunity Ahead
Summary Royalty Pharma's Q3 results met expectations, with a modest 2024 outlook increase, driven by strong portfolio performance and new royalty acquisitions. The CF franchise remains a key cash cow despite challenges, with Vertex's Venza triple development posing potential headwinds. With a compelling valuation, a $1 billion buyback, and a supportive pipeline, Royalty Pharma is a strong buy. Read the full article on Seeking AlphaRentabilidad de los accionistas
| RPRX | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | 4.7% | 5.3% | 1.1% |
| 1Y | 68.0% | 44.3% | 28.7% |
Rentabilidad vs. Industria: RPRX superó a la industria US Pharmaceuticals, que obtuvo un rendimiento del 44.3% el año pasado.
Rentabilidad vs. Mercado: RPRX superó al mercado US, que obtuvo un rendimiento del 28.7% el año pasado.
Volatilidad de los precios
| RPRX volatility | |
|---|---|
| RPRX Average Weekly Movement | 3.0% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: RPRX no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de RPRX (3%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1996 | 100 | Pablo Legorreta | www.royaltypharma.com |
Royalty Pharma plc opera como comprador de royalties biofarmacéuticos y financiador de la innovación en la industria biofarmacéutica en Estados Unidos. Su cartera consta de royalties sobre aproximadamente 35 terapias comercializadas y 20 productos candidatos en fase de desarrollo que abordan diversas áreas terapéuticas, como enfermedades raras, oncología, neurociencia, enfermedades infecciosas, hematología y diabetes. La empresa colabora en la financiación de la investigación y el desarrollo de JNJ-4804, un medicamento en fase de investigación para enfermedades autoinmunes.
Resumen de fundamentos de Royalty Pharma plc
| Estadísticas fundamentales de RPRX | |
|---|---|
| Capitalización bursátil | US$31.38b |
| Beneficios(TTM) | US$826.29m |
| Ingresos (TTM) | US$2.44b |
29.2x
Ratio precio-beneficio (PE)9.9x
Ratio precio-ventas (PS)¿Está RPRX sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de RPRX | |
|---|---|
| Ingresos | US$2.44b |
| Coste de los ingresos | -US$366.18m |
| Beneficio bruto | US$2.81b |
| Otros gastos | US$1.98b |
| Beneficios | US$826.29m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 1.86 |
| Margen bruto | 115.00% |
| Margen de beneficio neto | 33.86% |
| Ratio deuda/patrimonio | 90.1% |
¿Cómo se ha desempeñado RPRX a largo plazo?
Ver rendimiento histórico y comparativaDividendos
1.7%
Rentabilidad actual por dividendo47%
Ratio de pagos¿Paga RPRX dividendos fiables?
Ver historial de dividendos e índices de referencia de RPRX| fechas de dividendos de Royalty Pharma | |
|---|---|
| Fecha ex dividendo | May 15 2026 |
| Fecha de pago de dividendos | Jun 10 2026 |
| Días hasta ex dividendo | 11 days |
| Días hasta la fecha de pago de dividendos | 15 days |
¿Paga RPRX dividendos fiables?
Ver historial de dividendos e índices de referencia de RPRXAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/25 02:55 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Royalty Pharma plc está cubierta por 14 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Geoffrey Meacham | Citigroup Inc |
| Prem Chulaki | CrispIdea |